Propanc Biopharma (PPCB) vs Xenetic Biosciences (XBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Xenetic Biosciences is the larger company by market cap ($5.0 million vs $4.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PPCB | XBIO |
|---|---|---|
| Share price | $0.471 | $2.12 |
| Market cap | $4.63M | $4.97M |
| 1-day change | -5.55% | -4.07% |
| EPS (TTM) | $-17.62 | $-1.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $48.75 | $8.87 |
| 52-week low | $0.46 | $1.87 |
| Distance from 52-week high | -99.03% | -76.10% |
| Average volume | 1.79M | 87.31K |
| Shares outstanding | 9.83M | 2.34M |
| Employees | 2 | 2 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Propanc Biopharma
PPCB stock →Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies.
Healthcare · Biotechnology · 2 employees
About Xenetic Biosciences
XBIO stock →Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance.
Healthcare · Biotechnology · 2 employees
PPCB vs XBIO FAQ
Which is bigger, Propanc Biopharma or Xenetic Biosciences?
Xenetic Biosciences (XBIO) is larger, with a market capitalization of $4.97M compared with $4.63M for Propanc Biopharma (PPCB).
Are Propanc Biopharma and Xenetic Biosciences in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.